Madrigal Pharmaceuticals, Inc. (MDGL)
471.68
-15.30
(-3.14%)
USD |
NASDAQ |
Jun 08, 14:28
Madrigal Pharmaceuticals EPS Diluted (Quarterly) : -3.251 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Insmed, Inc. | -0.7591 |
| PTC Therapeutics, Inc. | -0.034 |
| Protagonist Therapeutics, Inc. | 0.0537 |
| Exelixis, Inc. | 0.7873 |
| United Therapeutics Corp. | 5.824 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -94.39M |
| Revenue (Quarterly) | 311.34M |
| Total Expenses (Quarterly) | 405.73M |
| Enterprise Value | 10.75B |
| Gross Profit Margin (Quarterly) | 91.25% |
| Profit Margin (Quarterly) | -30.32% |
| Earnings Yield | -2.71% |
| Normalized Earnings Yield | -2.695 |